Model‐based assessments of CYP3A‐mediated drug‐drug interaction risk of milademetan

• Main Authors: Ying Hong (Author), Tomoko Ishizuka (Author), Akiko Watanabe (Author), Masaya Tachibana (Author), Mark Lee (Author), Hitoshi Ishizuka (Author), Frank LaCreta (Author), Malaz Abutarif (Author)
• Format: Book
• Published: Wiley, 2021-11-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract Milademetan is a small‐molecule inhibitor of murine double minute 2 (MDM2) that is in clinical development for advanced solid tumors and hematological cancers, including liposarcoma and acute myeloid leukemia. Milademetan is a CYP3A and P‐glycoprotein substrate and moderate CYP3A inhibitor....